Print Page | Close Window

Decitabine - potential new treatment

Printed From: TNBC Foundation
Category: TNBC Forums
Forum Name: Let's Talk About Chemotherapy
Forum Description: A place to discuss Chemotherapy
URL: http://forum.tnbcfoundation.org/forum_posts.asp?TID=13354
Printed Date: Jun 18 2019 at 1:22pm
Software Version: Web Wiz Forums 12.01 - http://www.webwizforums.com


Topic: Decitabine - potential new treatment
Posted By: 123Donna
Subject: Decitabine - potential new treatment
Date Posted: May 25 2018 at 11:26am
Study identifies new potential treatment option for triple negative breast cancer (DECITABINE)

In a recent study published in the Journal of Clinical Investigation, Mayo Clinic researchers identified that an FDA drug approved for myelodysplastic syndrome may be useful to treat triple-negative breast cancer, which is one of the most aggressive and lethal types of breast cancer.

In this study, Mayo investigators identified that the drug 5-aza-2'-deoxycytidine (decitabine) which is FDA approved for the treatment of certain hematological (blood) cancers, could significantly inhibit the growth of triple-negative  https://medicalxpress.com/tags/breast/" rel="nofollow - breast cancers, and importantly this effect was also seen in tumors resistant to chemotherapy. This response was dependent on the presence of certain critical proteins called DNA methyl transferase proteins that are present in only a subset of triple negative breast cancers. This provides a way to identify which patients could benefit from this therapy.

"There is a great need to identify additional treatment options for  https://medicalxpress.com/tags/triple-negative+breast+cancer/" rel="nofollow - triple-negative breast cancer , which is one of the most difficult to treat subtypes of breast  https://medicalxpress.com/tags/cancer/" rel="nofollow - cancer ," says Mayo researcher Liewei Wang, M.D., Ph.D. "The study is a demonstration that we can take advantage of many existing FDA approved drugs to expand their usage by better understanding the mechanisms of how they work and applying them to other cancers."

This study was part of the ongoing work from the Breast Cancer Genome-Guided Therapy (BEAUTY) study, co-led by Matthew Goetz, M.D., a Mayo medical oncologist and Judy Boughey, M.D., a Mayo breast surgeon. The BEAUTY study generated patient derived xenografts (immortalizing breast tumor cells) from patients with breast cancer treated with chemotherapy.

"Patients whose tumor does not respond well to chemotherapy are known to be at significantly increased risk of  https://medicalxpress.com/tags/recurrent+breast+cancer/" rel="nofollow - recurrent breast cancer  and death," says Dr. Boughey. "Therefore our focus is to identify new treatment options for these  https://medicalxpress.com/tags/patients/" rel="nofollow - patients ."

In the living xenografts from BEAUTY, Mayo investigators found that when DNA methyl transferase proteins were present, decitabine showed an effect in triple-negative breast cancer at a low therapeutic dose. The low doses would result in less toxicity and might allow the drug to be used for a longer time, all of which might help to achieve greater therapeutic efficacy.

According to Dr. Goetz, plans are underway to prospectively study the impact of decitabine in a prospective clinical trial, called BEAUTY2, which is focused on women with triple negative  https://medicalxpress.com/tags/breast+cancer/" rel="nofollow - breast cancer  that is resistant to chemotherapy.

https://medicalxpress.com/news/2018-05-potential-treatment-option-triple-negative.html" rel="nofollow - https://medicalxpress.com/news/2018-05-potential-treatment-option-triple-negative.html



-------------
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15




Replies:
Posted By: mainsailset
Date Posted: May 27 2018 at 11:36pm
Every once in awhile an article comes along like this and I'm reminded just how far the research has brought treatment for Tneg. Hopefully we'll see more news on Clinical Trials.


-------------
dx 7/08 TN 14x6.5x5.5 cm tumor

3 Lymph nodes involved, Taxol/Sunitab+AC, 5/09 dbl masectomy, path 2mm tumor removed, lymphs all clear, RAD 32 finished 9/11/09. 9/28 CT clear 10/18/10 CT clear



Print Page | Close Window

Forum Software by Web Wiz Forums® version 12.01 - http://www.webwizforums.com
Copyright ©2001-2018 Web Wiz Ltd. - https://www.webwiz.net